ExpreS2ion Biotech holds extraordinary general meeting

• ExpreS2ion Biotech Holding AB held an extraordinary general meeting on Oct. 1, 2026.
• Shareholders adopted a board authorization to issue new shares, convertible debentures, or warrants through the next annual meeting.
• The mandate allows issuances with or without pre-emptive rights, funded in cash, in-kind contributions, or set-off.
• The decision authorizes potential capital raising, share-based payment for guarantee undertakings, put option obligations to Alumni Capital, or acquisitions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ExpreS2ion Biotech Holding AB published the original content used to generate this news brief on October 01, 2026, and is solely responsible for the information contained therein.